Cephalalgia最新文献

{"title":"Exploring the association between familial hemiplegic migraine genes (<i>CACNA1A</i>, <i>ATP1A2</i> and <i>SCN1A</i>) with migraine and epilepsy: A UK Biobank exome-wide association study.","authors":"Christian Staehr, Mette Nyegaard, Flemming W Bach, Palle Duun Rohde, Vladimir V Matchkov","doi":"10.1177/03331024241306103","DOIUrl":"https://doi.org/10.1177/03331024241306103","url":null,"abstract":"<p><strong>Background: </strong>Familial hemiplegic migraine (FHM) types 1-3 are associated with protein-altering genetic variants in <i>CACNA1A</i>, <i>ATP1A2</i> and <i>SCN1A</i>, respectively. These genes have also been linked to epilepsy. Previous studies primarily focused on phenotypes, examining genetic variants in individuals with characteristic FHM symptoms. This study aimed to investigate the association of FHM genetic variation with migraine and epilepsy, utilizing a genotype-first approach.</p><p><strong>Methods: </strong>Whole-exome sequence data from 454,706 individuals from the UK Biobank were examined for self-reported and inpatient-diagnosed migraine and epilepsy. Carriers were compared with non-carriers in a burden analysis using logistic regression while accounting for age, biological sex and UK Biobank assessment center. A machine learning-based approach was employed to predict whether variants resulted in gain-of-function (GoF), loss-of-function (LoF) or neutral effects.</p><p><strong>Results: </strong>Heterozygous carriers of GoF <i>CACNA1A</i> variants, LoF <i>ATP1A2</i> variants or neutral <i>SCN1A</i> variants were at increased risk of migraine. Homozygous carriers of neutral <i>SCN1A</i> variants were also associated with migraine but these carriers showed a reduced disease risk of epilepsy.</p><p><strong>Conclusions: </strong>Heterozygous genotypes in all three FHM genes were associated with migraine but not epilepsy in this genotype-focused study. Homozygous <i>SCN1A</i> genotypes also showed increased disease risk of migraine, yet these carriers were protected against epilepsy.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 1","pages":"3331024241306103"},"PeriodicalIF":5.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-induced reversible cerebral vasoconstriction syndrome: Lessons from the real world.","authors":"Pacôme Constant Dit Beaufils, Syrine Ben Mammou, Benoît Guillon, Solène de Gaalon","doi":"10.1177/03331024241312612","DOIUrl":"https://doi.org/10.1177/03331024241312612","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 1","pages":"3331024241312612"},"PeriodicalIF":5.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A reply, drug-induced reversible cerebral vasoconstriction syndrome: Lessons from the real world.","authors":"Sylvie Favreliere, Julien Mahe, Gwenaelle Veyrac, Jean-Philippe Neau, Claire Lafay-Chebassier, Marie-Christine Perault","doi":"10.1177/03331024241312620","DOIUrl":"https://doi.org/10.1177/03331024241312620","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 1","pages":"3331024241312620"},"PeriodicalIF":5.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prolactin-induced sensitization of trigeminal nociceptors promotes migraine co-morbidity in endometriosis.","authors":"Grace J Lee, Veronica Hode, Teodora Georgieva, Jill Rau, David W Dodick, Todd J Schwedt, Volker Neugebauer, Frank Porreca, Edita Navratilova","doi":"10.1177/03331024241313378","DOIUrl":"10.1177/03331024241313378","url":null,"abstract":"<p><strong>Background: </strong>Women with endometriosis are more likely to have migraine. The mechanisms underlying this co-morbidity are unknown. Prolactin, a neurohormone secreted and released into circulation from the anterior pituitary, can sensitize sensory neurons from female, but not male, rodents, monkeys and human donors.</p><p><strong>Methods: </strong>We used a syngeneic model of endometriosis to determine whether elevated prolactin levels can sensitize trigeminal ganglion neurons and increase vulnerability to migraine pain.</p><p><strong>Results: </strong>Mice with endometriotic lesions showed increased serum prolactin levels and developed persistent abdominal, but not cephalic, allodynia. However, inhalation of a transient receptor potential ankyrin 1 agonist, umbellulone, a known environmental trigger of headache in some patients, elicited cephalic allodynia in mice with endometriosis but not sham controls, suggesting that endometriosis can promote sensitization of trigeminal neurons and migraine attacks. Endometriosis dysregulated the expression of prolactin receptor isoforms in trigeminal neurons and increased their excitability measured by <i>in vitro</i> patch clamp electrophysiology. Inhibition of pituitary prolactin following a 2-week treatment with a dopamine receptor agonist, cabergoline, prevented cephalic allodynia elicited by activation of trigeminal afferents with umbellulone. Cabergoline treatment also normalized the expression of prolactin receptor isoforms in trigeminal ganglia and the hyperexcitability of trigeminal neurons.</p><p><strong>Conclusions: </strong>These data demonstrate that circulating prolactin in endometriosis promotes vulnerability to migraine through sensitization of trigeminal afferents. Clinically available dopamine receptor agonists or novel monoclonal antibodies targeting prolactin signaling may be effective for migraine prevention in women with endometriosis.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 1","pages":"3331024241313378"},"PeriodicalIF":5.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Building community and visibility: A year of social media growth for Cephalalgia.","authors":"Nina Riggins, Faraidoon Haghdoost","doi":"10.1177/03331024241310519","DOIUrl":"https://doi.org/10.1177/03331024241310519","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"45 1","pages":"3331024241310519"},"PeriodicalIF":5.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Communicate your findings with graphical abstract in <i>Cephalalgia</i> : Why and how?","authors":"Cédric Gollion, David Garcia-Azorin","doi":"10.1177/03331024241300883","DOIUrl":"https://doi.org/10.1177/03331024241300883","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 12","pages":"3331024241300883"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodology of drug trials in migraine: History and suggestions for the future.","authors":"Jes Olesen, Peer Tfelt-Hansen","doi":"10.1177/03331024241298642","DOIUrl":"https://doi.org/10.1177/03331024241298642","url":null,"abstract":"<p><p>There is a multitude of scientific papers and guideline papers on the methodology of drug trials in migraine. Here, we try to condense this into a single paper and to make proposals for future consideration. Literature known by the authors and from reference lists of relevant publications was used for the history. Relevant literature for our proposals was searched on PubMed. The main headings in published guidelines, namely, Patient selection, Trial design, Evaluation of results and Statistics, have remained unchanged over the years. Most of the methodology has remained unchanged but the changes that have taken place are important. Chronic migraine has been studied separately from episodic migraine, children and adolescents distinguished from adults, and migraine without aura from migraine with aura. In trial design, the group comparison design has taken priority over the cross-over design, but the latter is suggested for investigator driven, comparative, dose finding and aura trials because of its superior power. There is a confusing number of possible primary end points: number of migraine attacks, number of migraine days, number of headache days and number of 50% responders in prophylactic trials, whereas two-hour pain free is agreed in acute trials. However, also 24- and 48-hour pain free have been suggested and headache relief is sometimes still used against recommendations. Most bothersome symptom has been requested as a co-primary end point by Food and Drug Administration (FDA). Our future suggestions are meant to provide food for thought for future committee work. We suggest that most bothersome symptom needs to be discussed with FDA as a co-primary end point in acute trials. It could also be discussed whether episodic- and chronic migraine need separate study. Migraine with- and without aura should be studied separately. Furthermore, two-hour pain free should be maintained as the primary end point but the use of stricter outcome parameters should be explored. In prophylactic trials, migraine days are recommended over migraine attacks and over 50% responders. For investigator-initiated trials, comparative trials and proof of concept trials by small companies, the cross-over design with its superior power is still recommended. Finally, the need to lump various guidelines into one major document should be considered. The methodology of drug trials in migraine has been worked out in detail. It is important that these guidelines be followed in all clinical trials. We highlight several issues that merit attention in the future.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 12","pages":"3331024241298642"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstracts of the 20^th Biennial Migraine Trust International Symposium, London UK, 5th to 8th September 2024.","authors":"","doi":"10.1177/03331024241280496","DOIUrl":"https://doi.org/10.1177/03331024241280496","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 12","pages":"3331024241280496"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis.","authors":"B Lee Peterlin, Dale S Bond, Jessica Ailani, David W Dodick, Yingyi Liu, Rosa De Abreu Ferreira, Jonathan H Smith, Brett Dabruzzo, Peter J Goadsby, Joel M Trugman","doi":"10.1177/03331024241299753","DOIUrl":"10.1177/03331024241299753","url":null,"abstract":"<p><strong>Background: </strong>Migraine is associated with obesity. These analyses evaluated weight change with atogepant used as a preventive migraine treatment.</p><p><strong>Methods: </strong>Five atogepant clinical trials in adults with migraine (one phase 2b/3; four phase 3) were included: Three 12-week, randomized, placebo-controlled trials (episodic migraine: two; chronic migraine: one); one 40-week, open-label extension trial and one 52-week, standard care, randomized, long-term safety trial in episodic migraine. Change from baseline in body weight was measured.</p><p><strong>Results: </strong>Mean baseline body mass indexes were 30.0-30.7 kg/m² (pooled episodic migraine [United States only]) and 25.0-25.5 kg/m² (chronic migraine [East Asia, Europe, and North America]). More participants treated with atogepant 60 mg once-daily compared to placebo experienced ≥7% weight loss at any time in the pooled episodic migraine placebo-controlled trials (4.9% vs. 2.8%), chronic migraine placebo-controlled trial (5.8% vs. 2.0%), and pooled open-label extension and long-term safety trials (24.0% vs.14.7% in standard care [long-term safety only]). In the placebo-controlled trials, weight loss with atogepant 60 mg once-daily was observed at week 2 (pooled episodic migraine: -0.32%; chronic migraine: -0.39%), increasing at week 12 (pooled episodic migraine: -1.02%; chronic migraine: -1.50%); compared to weight gain with placebo at week 12 (pooled episodic migraine: +0.49%; chronic migraine: +0.10%). In the long-term episodic migraine studies, weight loss with atogepant 60 mg once-daily was observed at week 4 (long-term safety: -0.42%; open-label extension: -0.76%), increasing at week 40 (long-term safety: -2.38%; open-label extension: -2.09%).</p><p><strong>Conclusion: </strong>Atogepant was associated with modest dose- and duration-dependent weight loss.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifiers: NCT02848326 (CGP-MD-01); NCT03777059 (3101-301-002); NCT03700320 (long-term safety trial); NCT03939312 (open-label extension trial); NCT03855137 (3101-303-002).</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 12","pages":"3331024241299753"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142793991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The incremental burden and healthcare resource utilization among people with migraine in Europe: Insights from the 2020 European National Health and Wellness Survey.","authors":"Astrid Gendolla, Joshua D Brown, Amanda R Mercadante, Sheila Drakeley, Nikoletta Sternbach, Aaron Jenkins, Karin Hygge Blakeman, Gianluca Coppola","doi":"10.1177/03331024241276415","DOIUrl":"https://doi.org/10.1177/03331024241276415","url":null,"abstract":"<p><strong>Background: </strong>Despite the high prevalence of migraine in Europe, there is limited research on the burden among people with migraine.</p><p><strong>Methods: </strong>This cross-sectional survey used patient-reported data from the 2020 European National Health and Wellness Survey in France, Germany, Italy, Spain, and the United Kingdom. The study assessed the sociodemographic characteristics, health-related quality of life, depression, work productivity and activity impairment, and healthcare resource utilization among matched samples of people with diagnosed migraine (n = 3985) and compared to a matched cohort without migraine (n = 7970). The study also analyzed the burden across migraine subgroups stratified by the number of migraine headache days.</p><p><strong>Results: </strong>Lower health-related quality of life, higher depression, increased work productivity and activity impairment, and higher healthcare resource utilization were reported among people with migraine and ≥1 migraine headache days compared to matched people without migraine (all <i>p </i>< 0.001). Additionally, the incremental burden was also observed across migraine subgroups (1-3, 4-7, 8-14, and ≥15 migraine headache days) irrespective of the use of prescription medication compared to the matched controls without migraine.</p><p><strong>Conclusion: </strong>Migraine sufferers with ≥1 migraine headache days experienced worse productivity, lower quality of life, depression, and increased healthcare resource utilization than those without migraine, emphasizing the need for effective management strategies.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 12","pages":"3331024241276415"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}